2016
DOI: 10.2147/idr.s103101
|View full text |Cite
|
Sign up to set email alerts
|

Enzymatic degradation of in vitro Staphylococcus aureus biofilms supplemented with human plasma

Abstract: Enzymatic debridement is a therapeutic strategy used clinically to remove necrotic tissue from wounds. Some of the enzymes utilized for debridement have been tested against bacterial pathogens, but the effectiveness of these agents in dispersing clinically relevant biofilms has not been fully characterized. Here, we developed an in vitro Staphylococcus aureus biofilm model that mimics wound-like conditions and employed this model to investigate the antibiofilm activity of four enzymatic compounds. Human plasma… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
29
0
1

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 35 publications
(30 citation statements)
references
References 18 publications
0
29
0
1
Order By: Relevance
“…In this way, clinicians would be able to administer the enzymes to any patient presenting with a biofilm infection, regardless of the causative microorganisms, and have a reasonable expectation that the therapy will be effective. ␣-Amylase and cellulase are two inexpensive, commercially available GHs that target common linkages found in the EPS made by many different species of bacteria, and multiple studies have shown that they can inhibit and disrupt the preformed in vitro biofilms of a variety of bacterial species (22)(23)(24)(25)(26).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In this way, clinicians would be able to administer the enzymes to any patient presenting with a biofilm infection, regardless of the causative microorganisms, and have a reasonable expectation that the therapy will be effective. ␣-Amylase and cellulase are two inexpensive, commercially available GHs that target common linkages found in the EPS made by many different species of bacteria, and multiple studies have shown that they can inhibit and disrupt the preformed in vitro biofilms of a variety of bacterial species (22)(23)(24)(25)(26).…”
Section: Discussionmentioning
confidence: 99%
“…It has been shown that cellulase inhibits biofilm growth by Burkholderia cepacia and Pseudomonas aeruginosa on various abiotic surfaces commonly used in medical devices (22,23). Similarly, ␣-amylase, a GH that acts by cleaving the ␣-1,4 straight-chain linkage, has been previously shown to both inhibit biofilm formation and disrupt preformed biofilms of Vibrio cholerae, Staphylococcus aureus and P. aeruginosa in vitro (24)(25)(26). In this study, we aimed to hydrolyze the polysaccharides produced by S. aureus and P. aeruginosa in dual-species polymicrobial biofilms by targeting a pair of highly conserved glycosidic linkages.…”
mentioning
confidence: 99%
“…As of 2008, the FDA no longer recommends papain/urea for use. However, papain itself has been shown to have anti-biofilm properties in vitro , suggesting it possesses activity against bacterial proteins 136 . In fact, papain was shown to directly degrade the Actinomyces fimbrial proteins FimA and FimP in a dental plaque model 137 .…”
Section: Pharmacological Methods Of Controlling Established Infectionmentioning
confidence: 99%
“…The presence of persister cells allows the regeneration of the biofilm within the wound bed, which means that debridement is by no means a complete or permanent solution (Lebeaux et al, 2014). The efficacy of debridement can be improved by chemical and biological adjuvants, such as hydrogen peroxide and enzymes respectively (Watters et al, 2016). By causing the EPS matrix of the biofilm to degrade, and thus removing its principal means of protection and nutrition, the rate of wound healing is significantly increased (Kim et al, 2018).…”
Section: Current Treatment Strategies For Biofilms In Chronic Woundsmentioning
confidence: 99%